OBIO — Orchestra Biomed Holdings Share Price
- $214.09m
- $148.91m
- $2.76m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 4.85 | ||
Price to Tang. Book | 4.85 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 102.98 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -102.69% | ||
Return on Equity | -83.22% | ||
Operating Margin | -2858.97% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | 5.7 | -0.78 | 3.53 | 2.76 | 2.91 | 6.13 | -21.49% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. It is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- January 25th, 2023
- Public Since
- August 4th, 2020
- No. of Shareholders
- 595
- No. of Employees
- 56
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 37,824,571
- Address
- 150 Union Square Drive, NEW HOPE, 18938
- Web
- Phone
- +1 6463439298
- Auditors
- Ernst & Young LLP
Upcoming Events for OBIO
Similar to OBIO
908 Devices.
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Brainsway
NASDAQ Global Market
Castle Biosciences
NASDAQ Global Market
FAQ
As of Today at 21:29 UTC, shares in Orchestra Biomed Holdings are trading at $5.66. This share price information is delayed by 15 minutes.
Shares in Orchestra Biomed Holdings last closed at $5.66 and the price had moved by +25.78% over the past 365 days. In terms of relative price strength the Orchestra Biomed Holdings share price has underperformed the S&P500 Index by -10.84% over the past year.
The overall consensus recommendation for Orchestra Biomed Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOrchestra Biomed Holdings does not currently pay a dividend.
Orchestra Biomed Holdings does not currently pay a dividend.
Orchestra Biomed Holdings does not currently pay a dividend.
To buy shares in Orchestra Biomed Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.66, shares in Orchestra Biomed Holdings had a market capitalisation of $214.09m.
Here are the trading details for Orchestra Biomed Holdings:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: OBIO
Based on an overall assessment of its quality, value and momentum Orchestra Biomed Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Orchestra Biomed Holdings is $15.60. That is 175.62% above the last closing price of $5.66.
Analysts covering Orchestra Biomed Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$1.68 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Orchestra Biomed Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +13.57%.
As of the last closing price of $5.66, shares in Orchestra Biomed Holdings were trading -8.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Orchestra Biomed Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Orchestra Biomed Holdings' directors